Literature DB >> 21103665

ABO blood group as a potential risk factor for venous thromboembolism in acutely injured patients.

Sarah K Muellner1, Elliott R Haut, Michael B Streiff, John B Holcomb, Bryan A Cotton.   

Abstract

Venous thromboembolism (VTE) is a major health problem that results in a significant burden on hospitals and patients. VTE screening and prophylaxis protocols in trauma patients vary significantly among hospitals and providers. In addition, many patients develop VTE even in the absence of "high-risk" categories. Therefore, more research is needed to better understand and prevent VTE in these patients. ABO blood group has long been recognised as a risk factor for VTE, but its contribution to VTE risk in the trauma setting is poorly studied. This paper reviews the literature describing the link between ABO blood group and VTE risk and the implications for VTE screening and prophylaxis in trauma patients. The effect of ABO blood groups are genotype-dependent - in most populations the A1 allele and the B allele increase risk while A2, O1, and O2 decrease risk of VTE. ABO group is a major determinant of plasma von Willebrand factor (vWF) and factor VIII levels, thereby (partially) mediating the effects of ABO blood group on VTE susceptibility. In addition, ABH antigens alter plasma levels of vWF via clearance mechanisms, which are in turn mediated by ADAMTS13. ABO blood group is a risk factor for VTE that warrants further investigation in trauma patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21103665     DOI: 10.1160/TH10-08-0504

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  ABO blood group polymorphisms and risk for ischemic stroke and peripheral arterial disease.

Authors:  Adriano de Paula Sabino; Daniel Dias Ribeiro; Caroline Pereira Domingheti; Danyelle Romana Alves Rios; Luci Maria SantAna Dusse; Maria das Graças Carvalho; Ana Paula Fernandes
Journal:  Mol Biol Rep       Date:  2014-01-22       Impact factor: 2.316

2.  ABO blood groups and the risk of venous thrombosis in patients with inherited thrombophilia.

Authors:  Luca Spiezia; Elena Campello; Maria Bon; Tiziana Tison; Marta Milan; Paolo Simioni; Paolo Prandoni
Journal:  Blood Transfus       Date:  2012-10-11       Impact factor: 3.443

3.  Elevated Von Willebrand Factor Antigen Levels are an Independent Risk Factor for Venous Thromboembolism: First Report from North India.

Authors:  Sweta Rajpal; Jasmina Ahluwalia; Narender Kumar; Pankaj Malhotra; Varun Uppal
Journal:  Indian J Hematol Blood Transfus       Date:  2019-02-15       Impact factor: 0.900

4.  ABO blood types associated with the risk of venous thromboembolism in Han Chinese people: A hospital-based study of 200,000 patients.

Authors:  Xuefeng Sun; Jun Feng; Wei Wu; Min Peng; Juhong Shi
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

5.  Association of blood group and red blood cell transfusion with the incidence of antepartum, peripartum and postpartum venous thromboembolism.

Authors:  Chen Wang; Isabelle Le Ray; Brian Lee; Agneta Wikman; Marie Reilly
Journal:  Sci Rep       Date:  2019-09-19       Impact factor: 4.379

Review 6.  Systematic Review and Meta-Analysis of the Susceptibility of ABO Blood Groups to Venous Thromboembolism in Individuals with Factor V Leiden.

Authors:  Waleed M Bawazir
Journal:  Diagnostics (Basel)       Date:  2022-08-11

7.  ABO blood groups do not predict progression of traumatic intracranial hemorrhage.

Authors:  Alyssa M Tutunjian; Sandra S Arabian; Jacqueline Paolino; Elizabeth S Wolfe; Eric J Mahoney; Horacio M Hojman; Benjamin P Johnson; Nikolay Bugaev
Journal:  J Clin Neurosci       Date:  2021-06-23       Impact factor: 2.116

8.  Using electronic health record system triggers to target delivery of a patient-centered intervention to improve venous thromboembolism prevention for hospitalized patients: Is there a differential effect by race?

Authors:  Oluwafemi P Owodunni; Elliott R Haut; Dauryne L Shaffer; Deborah B Hobson; Jiangxia Wang; Gayane Yenokyan; Peggy S Kraus; Jonathan K Aboagye; Katherine L Florecki; Kristen L W Webster; Christine G Holzmueller; Michael B Streiff; Brandyn D Lau
Journal:  PLoS One       Date:  2020-01-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.